by Neoteryx, on February 14,2022
February 2022 — Device company Neoteryx, which is now part of the Trajan Scientific and Medical family, announces the release of a new tech note for research customers that use …
Read Storyby Neoteryx, on November 16,2021
November 2021 — The Mitra® microsampling device from US-based Neoteryx has been registered in Brazil as a Class 1 in vitro diagnostic (IVD) medical device by ANVISA, the Agência Nacional …
Read Storyby Neoteryx, on July 26,2021
TORRANCE, July 2021 — Medical device company Neoteryx announces that to support its customers in research, clinical trials, laboratory services, and healthcare networks around the world, it is releasing a …
Read Storyby Neoteryx, on June 3,2021
May 2021 — The World Anti-Doping Agency (WADA) Executive Committee released a Technical Document announcing it approved the use of innovative dried blood spot methods as a new way to …
Read Storyby Neoteryx, on March 25,2021
According to a March 12, 2021 article by Adam Bonislawski in Genomeweb, researchers at Stanford University are profiling responses to the COVID-19 vaccinations. The Stanford study investigates the effects of …
Read StoryThe latest product releases, company news and microsampling industry updates from Neoteryx.
If you don’t find the information & assets you need via the buttons below, please contact us here: press@neoteryx.com
Fact Sheet & FAQs
© Neoteryx 2021 | Privacy Policy | Sitemap
421 Amapola Ave
Torrance, CA 90501
This site is protected by reCAPTCHA and the Google Privacy
Policy and Terms of Service apply.
Mitra® devices are intended as a specimen collector and for the storage and transport of biological fluids. They are CE-IVD self-certified in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada, Thailand, and Ukraine. In the United States, Mitra devices are for Research Use Only (RUO). In some countries, Mitra devices may be used in clinical diagnostic laboratory systems after the laboratory has validated their complete system in compliance with relevant rules and regulations. Mitra is a registered trademark of Neoteryx, LLC.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use. hemaPEN® is a registered trademark owned by Trajan Scientific Australia Pty Ltd.
Copyright © 2022 Neoteryx, LLC, Part of the Trajan Family. All rights reserved.